Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Juergen Siekmann
Observed names:
J Siekmann,
J. SIEKMANN,
J. Siekmann
Institution:
Baxter (Austria)
Observed institutions:
Bielefeld University,
Baxter (Austria)
OpenAlex ID:
A5113795835
von Willebrand Disease in a Pediatric-based Population - Comparison of Type 1 Diagnostic Criteria and Use of the PFA-100® and a von Willebrand Factor/Collagen-binding Assay
2000
·
J.A. Dean
, V. S. Blanchette
, et al.
·
Thrombosis and Haemostasis
·
134
BAX 855, a PEGylated rFVIII product with prolonged half-life. Development, functional and structural characterisation.
2012
·
P L Turecek
, M J Bossard
, et al.
·
PubMed
·
107
Safety of PEGylated recombinant human full‐length coagulation factor VIII (BAX 855) in the overall context of PEG and PEG conjugates
2015
·
R. Stidl
, S. Fuchs
, et al.
·
Haemophilia
·
67
PDF
Development of a plasma- and albumin -free recombinant von Willebrand factor
2009
·
P. L. Turecek
, A. Mitterer
, et al.
·
Hämostaseologie
·
67
BAX 855, a PEGylated rFVIII product with prolonged half-life: Development, functional and structural characterisation
2012
·
M. J. Bossard
, M. Graninger
, et al.
·
Hämostaseologie
·
52
GEMMA and MALDI-TOF MS of reactive PEGs for pharmaceutical applications
2010
·
Jasmin Kemptner
, Martina Marchetti-Deschmann
, et al.
·
Journal of Pharmaceutical and Biomedical Analysis
·
31
Improved flow cytometric method to enumerate residual cells: Minimal linear detection limits for platelets, erythrocytes, and leukocytes
2002
·
J. Pichler
, D. Printz
, et al.
·
Cytometry
·
20
PDF
Biochemical and Functional Characterization of PEGylated rVWF.
2006
·
Peter L. Turecek
, Friedrich Scheiflinger
, et al.
·
Blood
·
11
Development of BAX 826, a Polysialylated Full-Length rFVIII with Significantly Improved PK Properties
2015
·
Peter L. Turecek
, Juergen Siekmann
, et al.
·
Blood
·
4
Modification of rVWF with Polysialic Acid: Biochemical and Functional Characterization in Mice with VWD.
2006
·
Peter L. Turecek
, Juergen Siekmann
, et al.
·
Blood
·
3
Herstellung und Charakterisierung von rekombinantem von Willebrand-Faktor zur therapeutischen Anwendung
1997
·
U. Schlokat
, B. Fischer
, et al.
·
Springer eBooks
·
3
Funktionelle Charakterisierung von plasmatischem und rekombinantem von-Willebrand-Faktor durch Bindung an Collagen
1999
·
J. Siekmann
, P. L. Turecek
, et al.
·
Springer eBooks
·
2
Absorption, Metabolism, Distribution, and Excretion of Longer Acting rFVIII (BAX 855) Following Intravenous Administration to Rats
2011
·
Reinhard Stidl
, Juergen Siekmann
, et al.
·
Blood
·
1
IMMUNATE S/D — A new Factor VIII — von-Willebrand Factor Complex Concentrate
2004
·
P. L. Turecek
, W. Schönhofer
, et al.
·
Springer eBooks
·
1
A high‐purity double virus inactivated FVIII/vWF concentrate (Immunate) in the successful treatment of patients with von Willebrand disease
2002
·
G Auerswald
, B Eberspächer
, et al.
·
Haemophilia
·
1
Rekombinanter von Willebrand-Faktor: Präklinik
1997
·
P. L. Turecek
, J. Siekmann
, et al.
·
Springer eBooks
·
1
PEG Modified rVWF Prolongs the Survival of Native rFVIII in Hemophilia A Knock-Out Mice.
2006
·
Peter L. Turecek
, Friedrich Scheiflinger
, et al.
·
Blood
Characterization of Factor VIII-Von Willebrand Factor (FVIII-VWF)-Complex Concentrates Under Shear Stress
2005
·
J. Siekmann
, H. P. Schwarz
, et al.
·
Springer eBooks
ChemInform Abstract: Proteinase Inhibitor Engineering by Chemical and Enzymic Semisynthesis
1995
·
H. R. WENZEL
, J. SIEKMANN
, et al.
·
ChemInform
Show more works
View as search
Works count:
20
Citation count:
505
H-index:
8
I10-index:
8
Year
Topic
Type